Sector News

Bayer names strategy chief Baumann as new CEO

February 25, 2016
Life sciences

Bayer named Werner Baumann, its head of strategy and a veteran at the drugmaker, as its new chief executive on Wednesday, in a move some industry watchers said could herald more deal-making in the German firm’s non-pharma markets.

Baumann, 53, will replace Marijn Dekkers, 58, on May 1, Bayer said, confirming a Reuters report published last week. Dekkers’ contract had initially been due to run until the end of 2016 but will be ended early.

Baumann, who joined Bayer in 1988, made a name for himself with the successful integration of rival drugmaker Schering in 2006 – at the time Bayer’s biggest-ever takeover – and was a driving force behind the acquisition of Merck & Co’s consumer health unit eight years later.

Investment bankers who know him describe Baumann as introverted and indifferent to executive trappings, but said this should not be confused with a lack of determination.

“Werner Baumann shouldn’t be underestimated. He won’t hesitate to do a deal if it fits,” one of them said.

Some bankers expect Bayer to do more deals in its non-pharma markets, given Baumann’s stated belief in a diversified healthcare strategy, similar to Johnson & Johnson’s.

Challenges loom for 150-year-old Bayer. The planned combination of DuPont and Dow Chemical creates a more formidable rival for Bayer’s pesticides and seeds unit.

In animal health, Bayer is set to become a second-tier player after major consolidation moves in the sector created four clear market leaders.

Baumann spent four years practising for the takeover of Schering, a $22 billion deal that restored aspirin inventor Bayer – at the time struggling with its drugs offering – to its pharmaceutical roots.

He helped develop a blueprint in 2002 to streamline mergers and subsequent integration projects, seeking to eliminate frictions that had hobbled Bayer in the past.

His handling of cutbacks in the integration of Schering while keeping staff motivated proved to be a career-booster for Baumann, who worked in Spain and the United States before returning to headquarters in 2002.

He became finance chief in 2010 before moving to take charge of strategy and portfolio management in 2014.

In the top job, Baumann will also have to show that Bayer’s previous bout of promising drug launches, such as anti-blindness treatment Eylea and stroke prevention pill Xarelto, can be sustained. (Writing by Maria Sheahan; Editing by Christoph Steitz and Mark Potter)

By Ludwig Burger

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.